Following breakthroughs in regenerative medicine technology and the maturation of the Regenerative Medicine Act and Regulations, Taiwan's cell therapy industry is accelerating the commercialization of new drug products.
Leveraging its robust patent portfolio and supply chain integration capabilities, GWOXI has successfully advanced multiple innovative technologies from clinical translation to commercialization, providing patients with novel treatment options.
Patent Portfolio and Technical Innovation: Building Global Competitiveness
GWOXI is deeply committed to the fields of cell therapy and regenerative medicine, ensuring its technological leadership through a comprehensive patent portfolio. To date, it has secured over 117 patents globally. These patents cover key technologies such as cell isolation and purification, amplification processes, pharmaceutical compositions, automated manufacturing, dosage form filling, and packaging and transportation. This further strengthens its global market competitiveness and attracts international partners to jointly advance the clinical application of cell therapy.
GWOXI has successfully established a standardized production process for mesenchymal stem cells, which improves the consistency of cell quality and therapeutic efficacy. The company has also received approval for multiple clinical trials to validate safety and efficacy in humans. Additionally, through AI-assisted analysis and high-throughput screening technology, GWOXI continues to optimize its cell therapy solutions, enhancing therapeutic outcomes and reducing costs. This lays a solid foundation for future commercialization.
Supply Chain Integration and Clinical Translation: Accelerating Product Commercialization.
GWOXI uses a vertical integration model that connects R&D, production, and clinical applications, ensuring its technology can be rapidly transferred to the market. The company owns a cell manufacturing center that meets PIC/S GMP standards and, through a CDMO (Contract Development and Manufacturing Organization) model, assists global partners in developing and producing cell therapy products. By adopting a flexible business model that includes licensing collaborations, joint development, and technology transfer, GWOXI accelerates the entry of its new drugs into different regional markets and enhances product value.
GWOXI is actively collaborating with international biotech and medical institutions to advance technology licensing and joint development, with the goal of expanding its global market.
Global Market Expansion Strategy: Market Trends and International Alignment.
Global Cell Therapy Market Trends
According to a report by Mordor Intelligence, the global cell therapy market is projected to reach $5.58 billion by 2025, with a Compound Annual Growth Rate (CAGR) of 17.05% between 2025 and 2030. This growth is primarily driven by the increasing prevalence of chronic diseases, a higher acceptance of regenerative medicine, and the development of allogeneic cell technologies.
GWOXI's Global Market Strategy
GWOXI is closely following these market trends, actively collaborating with leading international biotech companies, medical institutions, and investment funds to deepen its integration into the industry chain. With cell therapy products, PIC/S GMP standard facilities, and CDMO services at its core, the company is strengthening its alignment with the international market by promoting technology licensing and joint development to provide innovative cell therapy solutions to patients worldwide.
A New Era of Regenerative Medicine
Upholding its principles of "Innovation, Excellence, and Responsibility," GWOXI continues to advance the commercialization of new drugs. Based on its patent portfolio and supply chain integration, the company aims to build a world-class cell therapy brand and join hands with global partners to co-create a new era of regenerative medicine.